So Young Jang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
So Young Jang has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Eun-Jeong Kwon
Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea
2 shared publications - Sejoong Kim
Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea
2 shared publications - Eun Mi You
Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea
1 shared publication - Ho Jun Chin
Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea
1 shared publication - Hyejin Lee
Department of Family Medicine, Seoul National University Bundang Hospital
1 shared publication - Julee You
Department of Internal Medicine, Hallym University Dongtan Sacred Heart Hospital, Hwaseong, Republic of Korea
1 shared publication
Latest Publications
- Open Access
- 1 July 2025
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
- Vol. 44 (4) , 612-625
Evaluation of the novel ALK5 inhibitor EW-7197 on therapeutic efficacy in renal fibrosis using a three-dimensional chip model
Background: EW-7197, a potent oral ALK5 inhibitor, was assessed for its impact on transforming growth factor beta 1 (TGF-β1)–induced fibrosis in a three-dimensional (3D) renal fibrosis-on-a-chip and a mouse model. The evaluation included tubular epithelial- mesenchymal transition, angiogenesis, and inflammatory cytokine expression. Methods: In a 3D renal fibrosis-on-a-chip model, three cell types(kidney fibroblasts, human proximal tubular cells, and human umbilical vein endothelial cells) were cultured and treated with TGF-β1 and EW-7197. Alpha smooth muscle actin (α-SMA) and keratin 8 (KRT-8) was assessed, angiogenesis observed via confocal microscopy, and cytokine levels measured by polymerase chain reaction, immunoassay, and enzyme-linked immunosorbent assay. In a cisplatin-induced renal fibrosis mouse model, blood urea nitrogen levels, TGF-β, and Smad 2/3 were determined, and fibrosis was assessed with Masson’s trichrome stain. Results: The α-SMA expression was significantly lower in the EW-7197 group than in the TGF-β fibrosis group. TGF-β decreased the expression of the epithelial marker KRT-8, an effect that was reversed by EW-7197 and SB431542. In the TGF-β–induced fibrosis model, the length of the thick vessels was reduced, and the diameter of both thick and thin vessels was decreased, but EW-7197 reversed these effects. EW-7197 significantly reduced the messenger RNA expression of TGF-β and increased the levels of vascular endothelial growth factor receptor 2, interleukin (IL)-10, and IL-6. EW-7197 reduced the levels of secretory cytokines TGF-β1, TGF-β3, IL- 1β. In the cisplatin-induced renal fibrosis mouse model, EW-7197 reduced renal fibrosis by down-regulating TGF-β signaling. Conclusion: EW-7197 attenuated the TGF-β1–induced fibrotic cellular response in the 3D chip model and animal model. These findings indicate the potential effect of EW-7197 in attenuating renal fibrosis.
- 1 July 2025
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
- Vol. 44 (4) , 612-625
Open AccessEvaluation of the novel ALK5 inhibitor EW-7197 on therapeutic efficacy in renal fibrosis using a three-dimensional chip model
Background: EW-7197, a potent oral ALK5 inhibitor, was assessed for its impact on transforming growth factor beta 1 (TGF-β1)–induced fibrosis in a three-dimensional (3D) renal fibrosis-on-a-chip and a mouse model. The evaluation included tubular epithelial- mesenchymal transition, angiogenesis, and inflammatory cytokine expression. Methods: In a 3D renal fibrosis-on-a-chip model, three cell types(kidney fibroblasts, human proximal tubular cells, and human umbilical vein endothelial cells) were cultured and treated with TGF-β1 and EW-7197. Alpha smooth muscle actin (α-SMA) and keratin 8 (KRT-8) was assessed, angiogenesis observed via confocal microscopy, and cytokine levels measured by polymerase chain reaction, immunoassay, and enzyme-linked immunosorbent assay. In a cisplatin-induced renal fibrosis mouse model, blood urea nitrogen levels, TGF-β, and Smad 2/3 were determined, and fibrosis was assessed with Masson’s trichrome stain. Results: The α-SMA expression was significantly lower in the EW-7197 group than in the TGF-β fibrosis group. TGF-β decreased the expression of the epithelial marker KRT-8, an effect that was reversed by EW-7197 and SB431542. In the TGF-β–induced fibrosis model, the length of the thick vessels was reduced, and the diameter of both thick and thin vessels was decreased, but EW-7197 reversed these effects. EW-7197 significantly reduced the messenger RNA expression of TGF-β and increased the levels of vascular endothelial growth factor receptor 2, interleukin (IL)-10, and IL-6. EW-7197 reduced the levels of secretory cytokines TGF-β1, TGF-β3, IL- 1β. In the cisplatin-induced renal fibrosis mouse model, EW-7197 reduced renal fibrosis by down-regulating TGF-β signaling. Conclusion: EW-7197 attenuated the TGF-β1–induced fibrotic cellular response in the 3D chip model and animal model. These findings indicate the potential effect of EW-7197 in attenuating renal fibrosis.
- Open Access
- 1 January 2025
- Published by XMLink in Journal of Korean Medical Science
- Vol. 40 (36) , e242
Analysis of Self-Sufficiency and Factors Affecting Migration Between Medical Service Regions in Korea Among CKD Patients
You EM, et al. J Korean Med Sci. 2025 Aug;40:e242. https://doi.org/10.3346/jkms.2025.40.e242
- 1 January 2025
- Published by XMLink in Journal of Korean Medical Science
- Vol. 40 (36) , e242
Open AccessAnalysis of Self-Sufficiency and Factors Affecting Migration Between Medical Service Regions in Korea Among CKD Patients
You EM, et al. J Korean Med Sci. 2025 Aug;40:e242. https://doi.org/10.3346/jkms.2025.40.e242